共 221 条
[1]
Arnaldi G(2003)Diagnosis and complications of Cushing’s syndrome: a consensus statement J Clin Endocrinol Metab 88 5593-5602
[2]
Angeli A(2012)Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications J Endocrinol Invest 35 434-448
[3]
Atkinson AB(2008)Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement J Clin Endocrinol Metab 93 2454-2462
[4]
Bertagna X(2003)The pathophysiological consequences of somatostatin receptor internalization and resistance Endocr Rev 24 28-47
[5]
Cavagnini F(2006)The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas J Clin Endocrinol Metab 91 4482-4488
[6]
Chrousos GP(2002)SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile Eur J Endocrinol 146 707-716
[7]
Fava GA(2005)The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5 Eur J Endocrinol 152 645-654
[8]
Findling JW(2005)Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells Am J Physiol Endocrinol Metab 289 E278-E287
[9]
Gaillard RC(2009)Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial J Clin Endocrinol Metab 94 115-122
[10]
Grossman AB(2012)Pasireotide B2305 study group: a 12-month phase 3 study of pasireotide in Cushing’s disease N Engl J Med 366 914-924